Stock comparison
JOHNSON & JOHNSON is 2.2x more valuable than AstraZeneca PLC by market capitalization ($622.64 B vs $286.27 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 2.2x more valuable than AstraZeneca PLC by market capitalization ($622.64 B vs $286.27 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 2.2x more valuable than AstraZeneca PLC by market capitalization ($622.64 B vs $286.27 B).
| Metric | JNJ | AZN |
|---|---|---|
| Market cap | $622.64 B | $286.27 B |
| US-listed rank | #18 | #50 |
| Revenue (latest FY) | $94.19B | - |
| Net income (latest FY) | $26.80B | - |
| Net margin | 28.5% | - |
| P/E (trailing FY) | 23.2x | - |
| SEC filings | 990 | 1,004 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 2.2x more valuable than AstraZeneca PLC by market capitalization ($622.64 B vs $286.27 B).
Full pages: JOHNSON & JOHNSON and AstraZeneca PLC, or browse the full rankings.